ReviewClinics in liver disease2012
Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses.
Review in Clinics in liver disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 243 citations in OpenAlex.
- CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.Acta clinica Croatica · 2024Guideline
- Effects of Branched-Chain Amino Acids on Parameters Evaluating Sarcopenia in Liver Cirrhosis: Systematic Review and Meta-Analysis.Frontiers in nutrition · 2022Pooled it
- Physical exercise for people with cirrhosis.The Cochrane database of systematic reviews · 2018Pooled it
- Trial
- Salt consumption and mortality risk in cirrhotic patients: results from a cohort study.Journal of nutritional science · 2022Trial
- Trial
- Effect of non-alcoholic beer, diet and exercise on endothelial function, nutrition and quality of life in patients with cirrhosis.World journal of hepatology · 2020Trial
- Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis.Hepatology (Baltimore, Md.) · 2015Trial
- Article
- Article
- Radiological Assessment of Sarcopenia and Its Association with Metabolic Markers in Patients with Liver Cirrhosis.Journal of clinical medicine · 2026Article
- Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions.Clinical and experimental medicine · 2026Review
- Effects of caffeine supplementation on lipid profile and handgrip strength in cirrhotic patients: a randomized, placebo- controlled, clinical trial.BMC nutrition · 2025Article
- Review
- The Effect of Nutritional Education on Nutritional Status and Quality of Life in Patients with Liver Cirrhosis.Healthcare (Basel, Switzerland) · 2025Article
- Bioelectrical impedance analysis-derived phase angle predicts osteosarcopenia and mortality in patients with chronic liver disease.Scientific reports · 2025Article
- Sarcopenia as a Risk Factor in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Implantation.Diagnostics (Basel, Switzerland) · 2025Article
- Updates in Hospital Medicine: Liver Disease.Journal of Brown hospital medicine · 2025Article
- Prevalence and clinical relevance of sarcopenia in Chinese patients with porto-sinusoidal vascular disorder.Frontiers in medicine · 2025Article
- Knowledge, attitudes, and practices of liver cirrhosis patients regarding dietary nutrition.Frontiers in nutrition · 2025Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Malnutrition is the most common, reversible complication of cirrhosis that adversely affects survival, response to other complications, and quality of life. Sarcopenia, or loss of skeletal muscle mass, and loss of adipose tissue and altered substrate use as a source of energy are the 2 major components of malnutrition in cirrhosis. Current therapies include high protein supplementation especially as a late evening snack. Exercise protocols have the potential of aggravating hyperammonemia and portal hypertension. Recent advances in understanding the molecular regulation of muscle mass has helped identify potential novel therapeutic targets including myostatin antagonists, and mTOR resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.